CoChat
Sign Up
Cited by 28Prostate Cancer Treatment and ResearchUrinary Bladder and Prostate ResearchProstate Cancer Diagnosis and Treatment

Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer

van der Sluis, Tim M., Meuleman, Eric J.H., van Moorselaar, R. Jeroen A., Bui, Hong N., Blankenstein, Marinus A., Heijboer, Annemieke C., Vis, André N.·2012·BJU International
DOI 10.1111/j.1464-410x.2011.10652.x
Open this paper in CoChat — free account

Abstract

What's known on the subject? and What does the study add? The male steroid hormone metabolism is an important target in the treatment of prostatic diseases. However, present literature is inconsistent about intraprostatic concentrations of steroid hormones and the role of intraprostatic steroid hormones in the arise and the course of prostatic diseases is yet to be determined. Part II of this two‐piece mini‐review reviews the effect of medication that alters the male steroid hormone metabolism (i.e. 5‐alpha reductase inhibitors, androgen deprivation therapy) on intraprostatic steroid hormone concentrations. Better knowledge of the intraprostatic steroid hormone concentrations might lead to more individualized treatment and even to new medical targets. Androgen deprivation therapy (ADT) and 5‐α‐reductase (5AR) inhibition are used in the treatment of men with advanced or metastatic prostate cancer and benign prostatic hyperplasia (BPH), respectively. These drugs exert their effect by lowering androgen levels in the serum and allegedly, the prostate gland. It is, however, unknown whether (increased) intraprostatic androgen levels are associated with the pathogenesis of BPH and with the initiation and progression of prostate cancer. Also, it is unclear whether intraprostatic dihydrotestosterone (DHT) levels correlate with a response to initial hormonal therapy or with patient outcome. These uncertainties have resulted from the finding that serum testosterone levels do not necessarily reflect those in the prostate gland. Intraprostatic DHT levels of men being treated with 5AR inhibition, of those treated with ADT for hormone‐naive prostate cancer, and of those with castration‐resistant prostate cancer are all altered in an equivalent manner because of hormonal manipulation. Increased knowledge of the mechanisms of the androgenic steroid pathways in prostatic diseases, with a special focus on intraprostatic androgen levels, may lead to treatment that is tailored to the needs of the individual patient, and probably to new therapeutic targets as well.

Integrity signals

Registry

Crossref · 10.1111/j.1464-410x.2011.10652.x

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
van der Sluis, T. M., Meuleman, E. J. H., van Moorselaar, R. J. A., Bui, H. N., Blankenstein, M. A., Heijboer, A. C., & Vis, A. N.
Affiliations
Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Corresponding author
Vis, André N.
ORCID
Venue
BJU International
Publisher
Wiley
Published
2011-10-12
Volume
109
Issue
2
Pages
183-188
ISSN
  • 1464-4096 (ISSN-L)
  • 1464-410X
DOI
10.1111/j.1464-410x.2011.10652.x
OpenAlex
W1956569991
Cited by
28
References
28
Citations by year
2024: 1 · 2022: 3 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 3 · 2014: 1 · 2013: 6 · 2012: 5
FWCI
3.26
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • British Journal of Urology (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
Keywords
benign prostatic hyperplasia, prostate cancer, 5-alpha reductase inhibitors, androgen deprivation therapy, androgen metabolism, castration-resistant prostate cancer, hormone therapy response
MeSH terms
Contraindications, Adult, Androgen Antagonists, Humans, Hypogonadism, Gonadotropin-Releasing Hormone, Male, Prostatic Hyperplasia, Prostatic Neoplasms, Dihydrotestosterone, Testosterone, 5-alpha Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review